Scipio bioscience, a Paris, France-based biotechnology company developing a new generation of single-cell sequencing solutions, secured a €6.0 M Series A financing.
The round was led by M Ventures (Amsterdam, The Netherlands), the corporate venture capital arm of Merck, with particiaption from initial shareholders Seventure Partners’ Quadrivum I (Paris, France) and High-Tech Gründerfonds (Bonn, Germany) and additional investors Financière Arbevel (Paris, France) and investiere (Zürich, Switzerland).
The funding will accelerate the final development of its single-cell RNA-sequencing kit, as well as marketing and business development efforts to prepare for commercial launch in 2022.
Co-founded and led by Pierre Walrafen, PhD, CEO, and world-renowned biophysicist Prof Stuart Edelstein, President, Scipio bioscience develops a new generation of single-cell sequencing solutions, to answer the needs of clinical and basic research labs. The patented technology is based on an innovative chemical approach conceived by Prof Stuart Edelstein, The company, hosted in the iPEPS-ICM incubator of the Brain & Spine Institute (ICM, Pitié-Salpêtrière Hospital, Paris), has developed the protocol from the initial proof-of-concept studies to a prototype kit ready for beta-testing by collaborating research teams. Scipio bioscience was supported by a grant from the Région Île-de-France and the Programme d’Investissement d’Avenir, operated by BPI France.